With over 16 years of experience, Dana’s expertise in new product access is a result of her work with key Medicare and Medicaid policy staff, including medical directors, policy analysts, pharmacy administrators and pricing staff to facilitate coverage of and resolve access issues for newly FDA-approved or expanded oral and injectable drugs and biologics. Through these relationships, she maintains perspectives on payers’ new product uptake processes and needs for information related to client products and services, and provides insight and clarity to coverage, coding, payment and documentation issues that affect stakeholders.
As a Senior Consultant, Government Payer Liaison, Dana oversees research, analysis, and implications of federal and state health policy and regulatory initiatives from the Centers for Medicare and Medicaid services (CMS), Medicare, and Medicaid – particularly those that affect access and reimbursement for newly FDA approved branded specialty drugs and biologicals in oncology and rare diseases.
Dana is currently responsible for providing education and training on a variety of Medicare and Medicaid payer types including Medicare MACs (Part A and B), Medicare Advantage, Part D, Fee for Service and Managed Medicaid, and a variety of healthcare settings, providing perspectives on new product access and reimbursement, and working with new manufacturers to establish Part D Coverage Gap Agreements and develop and submit new HCPCS coding applications with CMS.
Dana graduated Phi Beta Kappa from Indiana University with a Bachelor of Arts degree. She is also certified as a Managed Healthcare Professional (MHP®) through the Insurance Education Program at America’s Health Insurance Plans (AHIP).
